Food and Drug Administration, HHS.
Final rule; correction.
The Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of February 9, 2006 (71 FR 6677). That document reclassified hepatitis A virus (HAV) serological assays from class III (premarket approval) into class II (special controls). That document inadvertently published with an error. This document corrects the error.
This rule is effective March 13, 2006.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Sally Hojvat, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 240-276-0496.End Further Info End Preamble Start Supplemental Information
In FR Doc. 06-1206, appearing on page 6677 in the Federal Register of Thursday, February 9, 2006, the following correction is made:
1. On page 6679, beginning in the first column, under section “VI. Analysis of Impacts,” the second paragraph is corrected to read:
The Regulatory Flexibility Act requires agencies to analyze regulatory options that would minimize any significant impact of a rule on small entities. Reclassification of HAV serological assays from class III into class II will relieve manufacturers of the cost of complying with the premarket approval requirements in section 515 of the act. Because reclassification will reduce regulatory costs with respect to these devices, the agency certifies that the final rule will not have a significant economic impact on a substantial number of small entities.Start Signature
Dated: February 21, 2006.
Linda S. Kahan,
Deputy Director, Center for Devices and Radiological Health.
[FR Doc. 06-1871 Filed 2-28-06; 8:45 am]
BILLING CODE 4160-01-S